0001408443
false
A8
00-0000000
QC
0001408443
2023-08-10
2023-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 10, 2023
MILESTONE PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
Québec |
|
001-38899 |
|
Not applicable |
(state or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
1111 Dr. Frederik-Philips Boulevard, |
|
|
Suite 420 |
|
|
Montréal, Québec CA |
|
H4M 2X6 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant's telephone number, including area code: (514) 336-0444
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section
12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Common Shares |
|
MIST |
|
The Nasdaq Stock Market LLC |
Indicate by check
mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth
company x
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. |
Results of Operations and Financial Condition. |
On August 10, 2023, Milestone Pharmaceuticals
Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023,
which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated
herein by reference.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
MILESTONE PHARMACEUTICALS INC. | |
| |
By: |
/s/ Amit Hasija | |
|
Amit Hasija | |
|
Chief Financial Officer | |
| |
Dated: August 10, 2023 | |
Exhibit 99.1
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
- NDA
submission for etripamil in patients with PSVT expected in October 2023
- Data
featured during oral session at Heart Rhythm 2023 Annual Meeting support the potential of etripamil in patients with AFib-RVR
- Enrollment
complete in Phase 2 ReVeRA study of etripamil in patients with AFib-RVR; topline data expected in fourth quarter of 2023
Montreal and Charlotte,
N.C., August 10, 2023 -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused
on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter
ended June 30, 2023, and provided a clinical and corporate update.
“The remainder of 2023 represents a transformative
time for the Company as we approach our first New Drug Application (NDA) submission for etripamil and continue to lay the groundwork required
to successfully launch what could serve as the first and only U.S. Food and Drug Administration (FDA) approved treatment for patients
to self-treat their paroxysmal supraventricular tachycardia (PSVT),” said Joseph Oliveto, President, and Chief Executive Officer
of Milestone Pharmaceuticals. “Expanding assessment of the potential clinical utility of etripamil, we have completed enrollment
in ReVeRA, our Phase 2 study of etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR), and we look forward
to sharing topline data from this study in the fourth quarter of this year.”
Recent Program Updates
Etripamil for
PSVT
| ● | NDA Submission for Etripamil Nasal Spray in
Patients with PSVT Expected in October. Milestone expects to submit its first NDA for etripamil, the Company’s investigational
calcium channel blocker that is administered by patients outside of the healthcare setting, in patients with PSVT in October. Based on
feedback from the FDA, data from the Company’s previously completed global Phase 3 clinical program, including the RAPID and RAPID-extension
studies, NODE-303 and NODE-301, are expected to fulfill the safety and efficacy requirements for the planned NDA submission. |
| ● | Results
from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT Published
in The Lancet. Results from the Company’s Phase 3 RAPID clinical study were
recently published in The Lancet. The publication, titled “Self-administered
Intranasal Etripamil Using a Symptom-Prompted, Repeat-Dose Regimen for Atrioventricular-Nodal
Dependent Supraventricular Tachycardia: The Randomised, Controlled RAPID Trial,”
can be accessed via the following link: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00776-6/fulltext. |
Etripamil for AFib-RVR
| ● | Data
Featured During Oral Session at Heart Rhythm 2023 Annual Meeting Support Potential of Etripamil
in Patients with AFib-RVR. Data from an analysis of a subset of patients with AFib-RVR
in the NODE-303 study, which evaluated etripamil in patients with PSVT, were featured
during an oral session at the Heart Rhythm 2023 Annual Meeting in May. Data demonstrated
that self-administration of etripamil in patients experiencing AFib-RVR episodes resulted
in a substantial reduction in ventricular rate which was sustained over 60 minutes. The safety
and tolerability data from the analysis of these AFib-RVR episodes were consistent with those
observed across prior studies in PSVT. |
| ● | Enrollment Complete in the ReVeRA Phase 2
Proof-of-Concept Trial in Patients with AFib-RVR, With Topline Data Expected in the Fourth Quarter of 2023. Enrollment is complete
in ReVeRA, Milestone's Phase 2 double-blind, placebo-controlled, proof-of-concept trial of etripamil nasal spray in emergency department
patients experiencing AFib-RVR. The trial, in which patients were randomized 1:1 to receive either 70 mg of etripamil or placebo, is designed
to assess the safety and efficacy of etripamil nasal spray to reduce elevated ventricular rates in patients with symptomatic AFib-RVR.
The primary endpoint will assess reduction in ventricular rate, with key secondary endpoints including the time to achieve the maximum
reduction in rate and duration of the effect. Milestone expects to report topline data from this trial in the fourth quarter of 2023. |
Second Quarter 2023
Financial Results
| ● | As of June 30, 2023, Milestone had cash,
cash equivalents, and short-term investments of $87.6 million and 33.4 million common shares issued and outstanding, with an additional
9.6 million common shares issuable upon exercise of pre-funded warrants. Cash resources as of June 30, 2023 are expected to fund
operations into mid-2025. |
| ● | Research and development expense for the second
quarter of 2023 was $8.6 million, compared with $10.7 million for the prior year period. For the six months ended June 30, 2023,
research and development expense was $18.9 million compared with $19.4 million for the prior year period. The decreases in research and
development expenses were related to decreases in clinical developmental costs and clinical personnel-related costs as a result of the
Company’s Phase 3 studies reaching completion. |
| ● | General and administrative expense for the second
quarter of 2023 was $4.4 million, compared with $3.9 million for the prior year period. For the six months ended June 30, 2023, general
and administrative expense was $8.3 million compared with $7.6 million for the prior year period. The increases were related to an increase
in personnel-related costs and consulting fees for general and administrative expenses. |
| ● | Commercial expense for the second quarter of
2023 was $3.4 million, compared with $2.2 million for the prior year period. For the six months ended June 30, 2023, commercial expense
was $5.7 million compared with $3.9 million for the prior year period. The increases were related to additional personnel and professional
costs required to expand capabilities and operations in anticipation of potential commercialization. |
| ● | For the second quarter of 2023, operating loss
was $16.4 million, compared to $16.8 million for the prior year period. For the six months ended June 30, 2023, Milestone's operating
loss was $31.9 million, compared to $30.9 million in the prior year period. |
About Paroxysmal
Supraventricular Tachycardia
Paroxysmal Supraventricular
Tachycardia (PSVT) is a highly symptomatic and impactful heart arrhythmia characterized by unpredictable attacks of a racing heart that
afflicts approximately two million Americans. Symptoms of PSVT, including palpitations, chest pressure, and shortness of breath are often
debilitating, causing the patient to stop their current activities or avoid pursuits altogether. The impact and morbidity from an attack
can be especially detrimental in patients with underlying cardiovascular or medical conditions, such as heart failure, obstructive coronary
disease, or dehydration. The uncertainty of when an episode of SVT will strike or how long it will persist can provoke anxiety in patients,
which can have a negative impact on their day-to-day life. Many doctors are unsatisfied by the lack of effective treatment options besides
a prolonged, unpleasant, and costly trip to the emergency department or, for some patients, an invasive ablation procedure.
About Atrial Fibrillation
with Rapid Ventricular Rate
Atrial fibrillation (AFib) is a common arrhythmia
marked by an irregular and often rapid heartbeat. AFib is estimated to affect five million patients in the United States, a prevalence
projected by the Centers for Disease Control to increase to twelve million patients by 2030. Atrial fibrillation with rapid ventricular
rate (AFib-RVR) is a condition that many patients with AFib experience and includes episodes of abnormally high heart rate, often with
symptoms of palpitations, shortness of breath, dizziness, and weakness. Oral calcium channel blockers and/or beta blockers are used to
reduce the heart rate in this condition. When AFib-RVR occurs, symptoms are often burdensome enough to cause patients to seek acute care
in the emergency department, where standard-of-care procedures include intravenous administration of calcium channel blockers or beta
blockers, or electrical cardioversion, under medical supervision. Milestone's initial market research indicates that 30-40% of patients
with AFib experience one or more symptomatic episodes of RVR per year that require treatment, suggesting a target addressable market of
approximately three to four million patients in 2030 for etripamil in patients with AFib.
About Etripamil
Etripamil, Milestone's
lead investigational product, is a novel calcium channel blocker nasal spray. It is designed to be a rapid-response therapy that is self-administered
by the patient, without the need for direct medical oversight, and is being developed for elevated and often highly symptomatic heart
rate attacks associated with PSVT and AFib-RVR. If approved, etripamil is intended to provide health care providers with a new tool to
enable virtual care and patient self-management, and to impart upon the patient a greater sense of control over their condition. Milestone
is conducting a comprehensive development program for etripamil, with Phase 3 trials completed and an NDA submission expected in October 2023
in paroxysmal supraventricular tachycardia (PSVT). Milestone also has a Phase 2 proof-of-concept trial that has completed enrollment and
will report topline data in patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the fourth quarter of
2023.
About Milestone
Pharmaceuticals
Milestone Pharmaceuticals
Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular
medicines. Milestone's lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of paroxysmal
supraventricular tachycardia (PSVT) and is in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation
with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States.
For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.
Forward-Looking
Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could,"
"demonstrate," "designed," "develop," "estimate," "expect," "may," "pending,"
"plan," "potential," "progress," "will" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements
are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained
in this press release include statements regarding the potential of etripamil to serve as a promising therapy for PSVT patients; the timing
of the NDA submission for etripamil nasal spray; the potential for etripamil to serve as the first and only FDA-approved treatment for
patients to self-treat their PSVT; the potential for clinical trial data from the Phase 2 ReVeRA program later this year; the ability
for the data from the Company’s previously completed global Phase 3 clinical program, including the RAPID and RAPID-extension studies,
NODE-303, and NODE-301, to fulfill the safety and efficacy requirements for the planned NDA submission; and our ability to fund operations
into the middle of 2025. Important factors that could cause actual results to differ materially from those in the forward-looking statements
include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy
and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results
of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and
whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic,
political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation and Russian hostilities
in Ukraine and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health
emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current
economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including
in its annual report on Form 10-K for the year ended December 31, 2022, under the caption "Risk Factors," as such
discussion may be updated from time to time by subsequent filings we may make with the U.S. Securities & Exchange Commission.
Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Milestone Pharmaceuticals
Inc.
Condensed Consolidated
Statements of Loss (Unaudited)
(in thousands of US dollars, except share
and per share data)
| |
Three months ended June 30, | | |
Six months ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | — | | |
$ | — | | |
$ | 1,000 | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | |
Research and development, net of tax credits | |
| 8,622 | | |
| 10,657 | | |
| 18,879 | | |
| 19,425 | |
General and administrative | |
| 4,445 | | |
| 3,918 | | |
| 8,334 | | |
| 7,561 | |
Commercial | |
| 3,369 | | |
| 2,231 | | |
| 5,725 | | |
| 3,867 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (16,436 | ) | |
| (16,806 | ) | |
| (31,938 | ) | |
| (30,853 | ) |
| |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 1,213 | | |
| 158 | | |
| 1,801 | | |
| 198 | |
Interest expense | |
| (820 | ) | |
| — | | |
| (856 | ) | |
| — | |
| |
| | | |
| | | |
| | | |
| | |
Net loss and comprehensive loss | |
$ | (16,043 | ) | |
$ | (16,648 | ) | |
$ | (30,993 | ) | |
$ | (30,655 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of shares and pre-funded warrants outstanding, basic and diluted | |
| 42,937,036 | | |
| 42,278,563 | | |
| 42,895,387 | | |
| 42,260,682 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (0.37 | ) | |
$ | (0.39 | ) | |
$ | (0.72 | ) | |
$ | (0.73 | ) |
Milestone Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands of US dollars, except share
data)
| |
June 30, 2023 | | |
December 31, 2022 | |
Assets | |
| | | |
| | |
| |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 32,591 | | |
$ | 7,636 | |
Short-term investments | |
| 55,000 | | |
| 56,949 | |
Research and development tax credits receivable | |
| 483 | | |
| 331 | |
Prepaid expenses | |
| 5,400 | | |
| 6,005 | |
Other receivables | |
| 1,092 | | |
| 882 | |
Total current assets | |
| 94,566 | | |
| 71,803 | |
Operating lease assets | |
| 2,175 | | |
| 2,423 | |
Property and equipment | |
| 278 | | |
| 257 | |
Total assets | |
$ | 97,019 | | |
$ | 74,483 | |
| |
| | | |
| | |
Liabilities, and Shareholders' Equity | |
| | | |
| | |
| |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable and accrued liabilities | |
$ | 6,287 | | |
$ | 5,644 | |
Operating lease liabilities | |
| 522 | | |
| 495 | |
Total current liabilities | |
| 6,809 | | |
| 6,139 | |
Operating lease liabilities, net of current portion | |
| 1,729 | | |
| 1,996 | |
Senior secured convertible notes | |
| 48,073 | | |
| — | |
Total liabilities | |
| 56,611 | | |
| 8,135 | |
| |
| | | |
| | |
Shareholders’ Equity | |
| | | |
| | |
Common shares, no par value, unlimited shares authorized 33,363,971 shares issued and outstanding as of June 30, 2023, 34,286,002 shares issued and outstanding as of December 31, 2022 | |
| 260,169 | | |
| 273,900 | |
Pre-funded warrants - 9,577,257 issued and outstanding as of June 30, 2023 and 8,518,257 as of December 31, 2022 | |
| 48,459 | | |
| 34,352 | |
Additional paid-in capital | |
| 29,114 | | |
| 24,437 | |
Accumulated deficit | |
| (297,334 | ) | |
| (266,341 | ) |
| |
| | | |
| | |
Total shareholders’ equity | |
| 40,408 | | |
| 66,348 | |
| |
| | | |
| | |
Total liabilities and shareholders’ equity | |
$ | 97,019 | | |
$ | 74,483 | |
Contact:
David Pitts
Argot Partners
212-600-1902
milestone@argotpartners.com
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Milestone Pharmaceuticals (NASDAQ:MIST)
Historical Stock Chart
From Sep 2024 to Oct 2024
Milestone Pharmaceuticals (NASDAQ:MIST)
Historical Stock Chart
From Oct 2023 to Oct 2024